Form 8-K - Current report:
SEC Accession No. 0000950170-25-069825
Filing Date
2025-05-13
Accepted
2025-05-13 08:15:10
Documents
13
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ck0001991792-20250513.htm   iXBRL 8-K 52225
2 EX-99.1 ck0001991792-ex99_1.htm EX-99.1 182773
3 GRAPHIC img89521117_0.jpg GRAPHIC 36479
  Complete submission text file 0000950170-25-069825.txt   419278

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001991792-20250513.xsd EX-101.SCH 26974
15 EXTRACTED XBRL INSTANCE DOCUMENT ck0001991792-20250513_htm.xml XML 5113
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41925 | Film No.: 25937284
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)